Verge Genomics and Stealth Bio Advance Novel Therapeutics in ALS

As the ALS space rides the momentum from the recent approval of Amylyx's Relyvrio, Verge Genomics and Stealth Biotherapeutics are each moving forward in early-stage clinical trials.